Opko Health Inc. (NASDAQ:OPK) – Equities researchers at Barrington Research cut their Q2 2019 earnings estimates for shares of Opko Health in a research note issued to investors on Wednesday, May 8th. Barrington Research analyst M. Petusky now anticipates that the biotechnology company will post earnings per share of ($0.10) for the quarter, down from their prior estimate of ($0.08). Barrington Research currently has a “Buy” rating and a $5.00 target price on the stock. Barrington Research also issued estimates for Opko Health’s Q3 2019 earnings at ($0.08) EPS, FY2019 earnings at ($0.40) EPS and FY2020 earnings at ($0.24) EPS.
Several other research firms have also commented on OPK. Zacks Investment Research lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Friday, March 8th. ValuEngine lowered shares of Opko Health from a “hold” rating to a “sell” rating in a research note on Wednesday, May 1st. One analyst has rated the stock with a sell rating and four have assigned a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus target price of $9.25.
Opko Health (NASDAQ:OPK) last announced its quarterly earnings results on Tuesday, May 7th. The biotechnology company reported ($0.14) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.06) by ($0.08). Opko Health had a negative net margin of 19.92% and a negative return on equity of 9.86%. The business had revenue of $222.50 million during the quarter, compared to the consensus estimate of $241.27 million. During the same period in the previous year, the business posted ($0.08) EPS. Opko Health’s revenue was down 12.7% compared to the same quarter last year.
Large investors have recently bought and sold shares of the business. Rhumbline Advisers increased its stake in Opko Health by 40.8% in the 4th quarter. Rhumbline Advisers now owns 475,850 shares of the biotechnology company’s stock valued at $1,432,000 after buying an additional 137,968 shares during the last quarter. Vanguard Group Inc increased its stake in shares of Opko Health by 2.1% during the 3rd quarter. Vanguard Group Inc now owns 29,660,750 shares of the biotechnology company’s stock worth $102,626,000 after purchasing an additional 614,442 shares during the last quarter. Paloma Partners Management Co purchased a new stake in shares of Opko Health during the 4th quarter worth approximately $319,000. Virtu Financial LLC purchased a new stake in shares of Opko Health during the 1st quarter worth approximately $173,000. Finally, Strs Ohio increased its stake in shares of Opko Health by 27.0% during the 4th quarter. Strs Ohio now owns 112,500 shares of the biotechnology company’s stock worth $338,000 after purchasing an additional 23,900 shares during the last quarter. Hedge funds and other institutional investors own 22.66% of the company’s stock.
In other news, CEO Phillip Md Et Al Frost acquired 907,000 shares of the firm’s stock in a transaction on Wednesday, May 8th. The stock was purchased at an average price of $2.11 per share, for a total transaction of $1,913,770.00. Following the purchase, the chief executive officer now owns 3,068,951 shares in the company, valued at approximately $6,475,486.61. The purchase was disclosed in a document filed with the SEC, which is available at the SEC website. In the last quarter, insiders acquired 1,788,250 shares of company stock valued at $4,079,880. Company insiders own 42.74% of the company’s stock.
Opko Health Company Profile
OPKO Health, Inc, a healthcare company, engages in the diagnostics and pharmaceuticals business in the United States, Ireland, Chile, Spain, Israel, Mexico, and internationally. The company's Diagnostics segment operates BioReference Laboratories, a clinical laboratory that offers laboratory testing services.
Further Reading: Investing in Growth Stocks
Receive News & Ratings for Opko Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opko Health and related companies with MarketBeat.com's FREE daily email newsletter.